<DOC>
	<DOC>NCT00778297</DOC>
	<brief_summary>This is a single blind, reference drug controlled, one center viral immunogenicity and tolerability study of FluvalAB FL-K-004 Trivalent Influenza Vaccine with 6 μg HA/strain/dos antigen content to assess immunogenicity and tolerability. The aim of the study is to assess the immunogenicity and tolerability of FluvalAB FL-K-004 trivalent influenza vaccine with 6 μg HA/strain/dos antigen content (study drug) in age groups 18-60 years and over 60 years, with the objective to verify efficacy and tolerability of the study drug according to CPMP/BWP/214/96: "Note for Guidance on Harmonization of Requirements for Influenza Vaccines", 12 March 1997.</brief_summary>
	<brief_title>Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult volunteers in good health aged over 18 years, both sexes; Full contractual capacity of the participants; Are in good health (as determined by vital signs and medical history); Negative urine or serum pregnancy test for females of childbearing potential; Are able to understand and comply with planned study procedures; Signed informed consent prior to initiation of study procedures; Absence of existence of any exclusion criteria. Known allergy to eggs or other components of the vaccine; History of GuillainBarré syndrome; Pregnancy or breast feeding or positive pregnancy test prior to vaccination; Immunosuppressive therapy in the preceding 36 months; Active neoplasm (i.e. requiring any form of antineoplastic therapy); Concomitant corticosteroid therapy, including inhaled corticosteroids; Psychiatric illness and/or concomitant psychiatric drug therapy; Immunoglobulin (or similar blood product) therapy within 3 months prior to vaccination; Vaccine therapy within 4 weeks prior to the study; Influenza vaccination within 6 months prior to the study; Chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the immune response; Documented HIV, HBV or HCV infection; Acute febrile respiratory illness within one week prior to vaccination; Experimental drug therapy within 1 month prior to vaccination; Alcohol or drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>prevention</keyword>
	<keyword>influenza</keyword>
	<keyword>infection</keyword>
	<keyword>vaccine</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Influenza in humans</keyword>
</DOC>